Charles River Laboratories Announces Third-Quarter 2020 Results

– Third-Quarter Revenue of $743.3 Million –

– Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 –

– Increases 2020 Guidance –

WILMINGTON, Mass.--(BUSINESS WIRE)--October 29, 2020--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2020. For the quarter, revenue was $743.3 million, an increase of 11.3% from $668.0 million in the third quarter of 2019.

Acquisitions contributed 2.2% to consolidated third-quarter revenue growth. The impact of foreign currency translation benefited reported revenue growth by 1.3%. Excluding the effect of these items, organic revenue growth was 7.8%, driven primarily by the Discovery and Safety Assessment and Manufacturing Support segments, with Research Models and Services also contributing.

On a GAAP basis, third-quarter net income attributable to common shareholders was $102.9 million, an increase of 41.3% from net income of $72.8 million for the same period in 2019. Third-quarter diluted earnings per share on a GAAP basis were $2.03, an increase of 39.0% from $1.46 for the third quarter of 2019. The GAAP net income and earnings per share increases were driven primarily by higher revenue, operating margin improvement, and venture capital investment gains. GAAP earnings per share included a gain from the Company’s venture capital and other strategic investments of $0.29 per share in the third quarter of 2020, compared to a loss of $0.01 per share for the same period in 2019. The Company’s venture capital and other strategic investment performance has been excluded from non-GAAP results.

On a non-GAAP basis, net income was $118.0 million for the third quarter of 2020, an increase of 40.8% from $83.8 million for the same period in 2019. Third‑quarter diluted earnings per share on a non-GAAP basis were $2.33, an increase of 37.9% from $1.69 per share for the third quarter of 2019. The non-GAAP net income and earnings per share increases were driven primarily by higher revenue and operating margin improvement, as well as a lower tax rate.

James C. Foster, Chairman, President and Chief Executive Officer, said, “Our exceptional third-quarter performance is indicative of several important factors: that our flexible and reliable outsourced solutions resonate with clients even more today than ever before; that our research model clients are already resuming their research activities; that the market environment remains robust; and that we are generating greater operating leverage across our businesses as a result of our efforts to build a more scalable and nimble organization.”

“The COVID-19 crisis has emphasized the strength and resilience of our business model, our differentiated portfolio, and our unwavering focus on the client experience, which collectively are enhancing our position as the leading, early stage contract research organization. As our clients focus on scientific innovation and invest more in their preclinical pipelines, we believe we will remain their partner of choice to move their early-stage programs forward,” Mr. Foster concluded.

Third-Quarter Segment Results
Research Models and Services (RMS)

Revenue for the RMS segment was $151.9 million in the third quarter of 2020, an increase of 14.6% from $132.5 million in the third quarter of 2019. The HemaCare and Cellero acquisitions, which were completed in January 2020 and August 2020, respectively, contributed 11.1% to third-quarter RMS revenue. Organic revenue growth of 2.0% was driven primarily by higher research model services revenue, particularly the Genetically Engineered Models and Services (GEMS) business, as well as strong demand for research models in China, which rebounded from the COVID-19 pandemic earlier than other geographic regions. Demand for research models outside of China improved significantly on a sequential basis as clients resumed more normalized research activities following COVID-19-related disruptions earlier in the year. As a result, client ordering trends for research models moved closer to pre-COVID-19 levels during the third quarter, particularly in Europe, but remained moderately below prior-year levels.

In the third quarter of 2020, the RMS segment’s GAAP operating margin decreased to 24.4% from 25.9% in the third quarter of 2019. The decrease was primarily due to acquisition-related amortization costs associated with HemaCare and Cellero. On a non-GAAP basis, the operating margin increased to 27.7% from 26.5% in the third quarter of 2019, primarily due to operating leverage from higher revenue, as well as the benefit of operating efficiency initiatives, including cost controls associated with our COVID-19 response.

Discovery and Safety Assessment (DSA)

Revenue for the DSA segment was $461.2 million in the third quarter of 2020, an increase of 9.8% from $420.1 million in the third quarter of 2019. Organic revenue growth of 8.6% was driven by strong demand in both the Discovery Services and Safety Assessment businesses.

In the third quarter of 2020, the DSA segment’s GAAP operating margin increased to 19.6% from 15.5% in the third quarter of 2019. On a non-GAAP basis, the operating margin increased to 25.2% from 22.1% in the third quarter of 2019. The GAAP and non-GAAP operating margin increases were driven primarily by operating leverage from higher revenue and the benefit of operating efficiency initiatives.

Manufacturing Support (Manufacturing)

Revenue for the Manufacturing segment was $130.2 million in the third quarter of 2020, an increase of 12.9% from $115.3 million in the third quarter of 2019. Organic revenue growth was 11.5%, driven primarily by robust demand in the Biologics Testing Solutions (Biologics) business. Revenue for the Microbial Solutions business increased in the third quarter and the growth rate improved from the second-quarter level, due primarily to gradual improvement in the backlog of delayed instrument installations related to the COVID-19 pandemic.

In the third quarter of 2020, the Manufacturing segment’s GAAP operating margin increased to 37.1% from 34.0% in the third quarter of 2019. On a non-GAAP basis, the operating margin increased to 39.1% from 36.4% in the third quarter of 2019. The GAAP and non-GAAP operating margin increases were driven primarily by operating leverage from robust revenue growth in the Biologics business, as well as contributions from the Avian Vaccine business. The elimination of duplicate costs associated with last year’s transition to the new Biologics facility also benefited the year-over-year operating margin comparison.

Increases 2020 Guidance

The Company is increasing its 2020 financial guidance, which was previously provided on August 5, 2020, primarily as a result of the better-than-expected third quarter performance. The revenue loss from the COVID-19 pandemic will be approximately $70 million in 2020, which is favorable to its prior estimate of approximately $100 million.

The Company’s revenue, earnings per share, and free cash flow guidance is as follows:

2020 GUIDANCE	CURRENT	PRIOR
Revenue growth, reported	9.5% – 10.5%	7.5% – 9.0%
Less: Contribution from acquisitions (1)	(4.0%) – (4.5%)	~(4.0%)
Unfavorable/(favorable) impact of foreign exchange	0.0% – (0.5%)	~0.5%
Revenue growth, organic (2)	5.0% – 6.0%	4.0% – 5.5%
GAAP EPS estimate	$5.80 – $5.90	$4.70 – $5.00
Acquisition-related amortization	$1.75 – $1.80	~$1.75
Charges related to global efficiency initiatives (3)	~$0.15	$0.25 – $0.30
Acquisition-related adjustments (4)	$0.25 – $0.30	$0.20 – $0.25
Other items (5)	~$0.25	$0.25 – $0.32
Venture capital and other strategic investment losses/(gains), net (6)	($0.49)	($0.20)
Non-GAAP EPS estimate	$7.75 – $7.85	$7.05 – $7.35
Free cash flow (7)	~$415 million	$350 – $365 million

Footnotes to Guidance Table:

(1) The contribution from acquisitions reflects only those acquisitions that have been completed.

(2) Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign currency translation.

(3) These charges, which primarily include severance and other costs, relate primarily to the Company’s planned efficiency initiatives. Other projects in support of global productivity and efficiency initiatives are expected, but these charges reflect only the decisions that have already been finalized.

(4) These adjustments are related to the evaluation and integration of acquisitions, and primarily include transaction, advisory, and certain third-party integration costs, as well as certain costs associated with acquisition-related efficiency initiatives.

(5) These items primarily relate to charges of approximately $0.15 associated with the planned termination of the Company’s U.S. pension plan in the second half of 2020, as well as charges of approximately $0.10 primarily associated with U.S. and international tax legislation that necessitated changes to the Company’s international financing structure.

(6) Venture capital and other strategic investment performance only includes recognized gains or losses. The Company does not forecast the future performance of these investments.

(7) The reconciliation of the current 2020 free cash flow guidance is as follows: Cash flow from operating activities of approximately $545 million, less capital expenditures of approximately $130 million, results in free cash flow of approximately $415 million.

Webcast

Charles River has scheduled a live webcast on Thursday, October 29, at 9:30 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.

Estimates of COVID-19 Impact

In this press release, the Company has provided its estimates for the impact from the COVID-19 pandemic, including on the Company's revenue. These estimates were determined using methodologies and assumptions that vary depending on the specific reporting segment and situation. For the Research Models and Services segment, estimates were primarily based on comparisons to daily historical research model sales volumes prior to the COVID-19 pandemic and the subsequent reduction in research model order activity associated with our clients’ COVID-19 pandemic-related site closures and/or their reduced on-site activity, as well as our discussions with clients, particularly of our research model services and HemaCare businesses, with regard to revenue expectations and operational impacts from the COVID-19 pandemic. For the Discovery and Safety Assessment segment, estimates were based on multiple factors including, but not limited to, discussions with clients with regard to the cause of delays to discovery projects and safety assessment studies, location-specific actions to ensure employee safety in our facilities, the impact of remote versus in-person activities and services, and supply chain delays and other resource constraints. For the Manufacturing Support segment, estimates were based on multiple factors including, but not limited to, analysis of the sales impact due to the COVID-19 pandemic, assessments of idle instruments and the related revenue streams due to the inability to access clients’ sites, as well as discussions with clients with regard to their revenue expectations and operations. Further, we assumed for the purposes of formulating these estimates that (1) restrictions on economic activity, including stay-in-place orders and other similar government actions, will largely not be re-imposed for the remainder of the fiscal year; (2) the global economy, as it relates to demand for Charles River’s products and services, will gradually improve through the remainder of 2020; and (3) most of the Company’s essential personnel will be able to work on-site; and (4) that the Company will have adequate supplies and resources to support its businesses. In addition, the estimated revenue loss related to COVID-19 is expected to be partially offset by incremental work on clients’ COVID-19 programs. Because these estimates and assumptions involve risks and uncertainties, actual events and results may differ materially from these estimates and assumptions, and Charles River assumes no obligation and expressly disclaims any duty to update them.

Non-GAAP Reconciliations

The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, which exclude the amortization of intangible assets, and other charges related to our acquisitions; expenses associated with evaluating and integrating acquisitions and divestitures, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our efficiency initiatives; the write-off of deferred financing costs and fees related to debt financing; third-party costs associated with the remediation of unauthorized access into our information systems detected in March 2019; the non-cash tax benefit related to our international financing structure; charges related to the planned settlement of our U.S. pension plan; charges recorded in connection with the modification of our option to purchase equity in one of our joint ventures; investment gains or losses associated with our venture capital and other strategic investments; and adjustments related to the recognition of deferred tax assets expected to be utilized as a result of changes to the our international financing structure. This press release also refers to our revenue in both a GAAP and non-GAAP basis: “organic revenue growth,” which we define as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. Commencing in the first quarter of 2019, we exclude the performance of our venture capital and other strategic investments due to the determination that such investment gains or losses are not core to our overall operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.

Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the impact of the COVID-19 pandemic; the projected future financial performance of Charles River and our specific businesses; the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to the impact of acquisitions, including the acquisition of HemaCare and Cellero, on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and spending trends by our clients; and Charles River’s future performance as delineated in our revised forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, enhanced efficiency initiatives, and the assumptions surrounding the COVID-19 pandemic that form the basis for our revised annual guidance. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the COVID-19 pandemic, its duration, its impact on our business, results of operations, financial condition, liquidity, business practices, operations, suppliers, third party service providers, clients, employees, industry, ability to meet future performance obligations, ability to efficiently implement advisable safety precautions, and internal controls over financial reporting; the COVID-19 pandemic’s impact on client demand, the global economy and financial markets; the ability to successfully integrate businesses we acquire; the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; the impact of Brexit; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 11, 2020 and the Quarterly Report on Form 10-Q as filed on August 5, 2020, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

SCHEDULE 1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands, except for per share data)

	Three Months Ended						Nine Months Ended
	September 26, 2020			September 28, 2019			September 26, 2020			September 28, 2019

Service revenue	$	580,774		$	523,169		$	1,677,927		$	1,479,991
Product revenue		162,526			144,782			455,016			450,097
Total revenue		743,300			667,951			2,132,943			1,930,088
Costs and expenses:
Cost of services provided (excluding amortization of intangible assets)		377,226			351,894			1,124,988			1,014,063
Cost of products sold (excluding amortization of intangible assets)		76,800			69,941			234,382			220,028
Selling, general and administrative		128,289			129,509			385,902			388,024
Amortization of intangible assets		28,232			23,805			83,869			65,611
Operating income		132,753			92,802			303,802			242,362
Other income (expense):
Interest income		179			385			771			838
Interest expense		(18,867	)		(5,698	)		(53,286	)		(36,520	)
Other income (expense), net		21,211			(14,254	)		23,400			(8,161	)
Income from operations, before income taxes		135,276			73,235			274,687			198,519
Provision (benefit) for income taxes		32,665			(317	)		53,571			24,970
Net income		102,611			73,552			221,116			173,549
Less: Net (expense) income attributable to noncontrolling interests		(298	)		742			3			1,878
Net income attributable to common shareholders	$	102,909		$	72,810		$	221,113		$	171,671

Earnings per common share
Net income attributable to common shareholders:
Basic	$	2.07		$	1.49		$	4.47		$	3.53
Diluted	$	2.03		$	1.46		$	4.39		$	3.46

Weighted-average number of common shares outstanding;
Basic		49,703			48,818			49,482			48,682
Diluted		50,702			49,715			50,371			49,627

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

SCHEDULE 2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except per share amounts)


	September 26, 2020			December 28, 2019
Assets
Current assets:
Cash and cash equivalents	$	242,879		$	238,014
Trade receivables, net		572,058			514,033
Inventories		181,367			160,660
Prepaid assets		69,481			52,588
Other current assets		74,489			56,030
Total current assets		1,140,274			1,021,325
Property, plant and equipment, net		1,037,212			1,044,128
Operating lease right-of-use assets, net		168,379			140,085
Goodwill		1,777,642			1,540,565
Client relationships, net		732,408			613,573
Other intangible assets, net		70,370			75,840
Deferred tax assets		39,515			44,659
Other assets		247,538			212,615
Total assets	$	5,213,338		$	4,692,790

Liabilities, Redeemable Noncontrolling Interests and Equity
Current liabilities:
Current portion of long-term debt and finance leases	$	47,946		$	38,545
Accounts payable		96,758			111,498
Accrued compensation		191,295			158,617
Deferred revenue		172,336			171,805
Accrued liabilities		151,061			139,118
Other current liabilities		127,618			90,598
Total current liabilities		787,014			710,181
Long-term debt, net and finance leases		1,968,161			1,849,666
Operating lease right-of-use liabilities		146,578			116,252
Deferred tax liabilities		202,392			167,283
Other long-term liabilities		183,695			182,933
Total liabilities		3,287,840			3,026,315
Redeemable noncontrolling interests		24,033			28,647
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.01 par value; 120,000 shares authorized; 49,882 shares issued and 49,736 shares outstanding as of September 26, 2020, and 48,936 shares issued and 48,936 shares outstanding as of December 28, 2019		499			489
Additional paid-in capital		1,614,185			1,531,785
Retained earnings		501,442			280,329
Treasury stock, at cost, 146 and 0 shares, as of September 26, 2020 and December 28, 2019, respectively		(23,905	)		-
Accumulated other comprehensive loss		(195,281	)		(178,019	)
Total equity attributable to common shareholders		1,896,940			1,634,584
Noncontrolling interest		4,525			3,244
Total equity		1,901,465			1,637,828
Total liabilities, redeemable noncontrolling interests and equity	$	5,213,338		$	4,692,790

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

SCHEDULE 3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)

		Nine Months Ended
		September 26, 2020			September 28, 2019
	Cash flows relating to operating activities
	Net income	$	221,116		$	173,549
	Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization		174,048			146,262
	Stock-based compensation		40,973			43,429
	Deferred income taxes		(3,131	)		(25,092	)
	Gain on venture capital and strategic equity investments, net		(32,226	)		(5,724	)
	Other, net		16,902			4,865
	Changes in assets and liabilities:
	Trade receivables, net		(51,456	)		(24,491	)
	Inventories		(14,055	)		(12,981	)
	Accounts payable		(12,327	)		24,481
	Accrued compensation		29,438			(23,320	)
	Deferred revenue		(1,308	)		(1,556	)
	Customer contract deposits		9,887			(7,586	)
	Other assets and liabilities, net		30,335			8,423
	Net cash provided by operating activities		408,196			300,259
	Cash flows relating to investing activities
	Acquisition of businesses and assets, net of cash acquired		(419,146	)		(515,647	)
	Capital expenditures		(78,706	)		(76,675	)
	Purchases of investments and contributions to venture capital investments		(19,887	)		(17,664	)
	Proceeds from sale of investments		5,810			15
	Other, net		(1,192	)		(660	)
	Net cash used in investing activities		(513,121	)		(610,631	)
	Cash flows relating to financing activities
	Proceeds from long-term debt and revolving credit facility		1,411,954			2,071,175
	Proceeds from exercises of stock options		43,806			26,982
	Payments on long-term debt, revolving credit facility, and finance lease obligations		(1,320,961	)		(1,798,620	)
	Purchase of treasury stock		(23,905	)		(18,040	)
	Other, net		(4,417	)		(10,516	)
	Net cash provided by financing activities		106,477			270,981
	Effect of exchange rate changes on cash, cash equivalents, and restricted cash		5,825			8,793
	Net change in cash, cash equivalents, and restricted cash		7,377			(30,598	)
	Cash, cash equivalents, and restricted cash, beginning of period		240,046			197,318
	Cash, cash equivalents, and restricted cash, end of period	$	247,423		$	166,720

	Supplemental cash flow information:
	Cash and cash equivalents	$	242,879		$	164,759
	Restricted cash included in Other current assets		2,968			534
	Restricted cash included in Other assets		1,576			1,427
	Cash, cash equivalents, and restricted cash, end of period	$	247,423		$	166,720

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

SCHEDULE 4
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)⁽¹⁾
(in thousands, except percentages)

		Three Months Ended				Nine Months Ended
		September 26, 2020		September 28, 2019		September 26, 2020		September 28, 2019
Research Models and Services
	Revenue	$	151,910	$	132,546	$	414,455	$	405,772
	Operating income		37,108		34,385		68,325		103,729
	Operating income as a % of revenue		24.4 %		25.9 %		16.5 %		25.6 %
	Add back:
	Amortization related to acquisitions		4,010		341		15,581		1,042
	Severance		27		381		527		1,106
	Acquisition related adjustments ⁽²⁾⁽³⁾		922		-		1,499		2,201
	Site consolidation costs, impairments and other items		(59)		-		200		257
	Total non-GAAP adjustments to operating income	$	4,900	$	722	$	17,807	$	4,606
	Operating income, excluding non-GAAP adjustments	$	42,008	$	35,107	$	86,132	$	108,335
	Non-GAAP operating income as a % of revenue		27.7 %		26.5 %		20.8 %		26.7 %

	Depreciation and amortization	$	9,455	$	4,895	$	27,333	$	14,198
	Capital expenditures	$	3,552	$	5,818	$	15,585	$	14,979

Discovery and Safety Assessment
	Revenue	$	461,177	$	420,079	$	1,342,424	$	1,179,793
	Operating income		90,348		64,995		234,872		175,214
	Operating income as a % of revenue		19.6 %		15.5 %		17.5 %		14.9 %
	Add back:
	Amortization related to acquisitions		22,191		21,560		68,326		58,067
	Severance		423		1,848		3,987		2,533
	Acquisition related adjustments ⁽³⁾		461		4,524		2,845		8,516
	Site consolidation costs, impairments and other items		2,938		(207)		5,872		(207)
	Total non-GAAP adjustments to operating income	$	26,013	$	27,725	$	81,030	$	68,909
	Operating income, excluding non-GAAP adjustments	$	116,361	$	92,720	$	315,902	$	244,123
	Non-GAAP operating income as a % of revenue		25.2 %		22.1 %		23.5 %		20.7 %

	Depreciation and amortization	$	42,707	$	39,898	$	125,138	$	111,231
	Capital expenditures	$	15,532	$	21,141	$	46,436	$	45,130

Manufacturing Support
	Revenue	$	130,213	$	115,326	$	376,064	$	344,523
	Operating income		48,246		39,253		132,288		103,893
	Operating income as a % of revenue		37.1 %		34.0 %		35.2 %		30.2 %
	Add back:
	Amortization related to acquisitions		2,150		2,204		6,614		6,802
	Severance		333		248		1,985		549
	Acquisition related adjustments ⁽³⁾		-		62		(421)		218
	Site consolidation costs, impairments and other items		169		180		169		1,485
	Total non-GAAP adjustments to operating income	$	2,652	$	2,694	$	8,347	$	9,054
	Operating income, excluding non-GAAP adjustments	$	50,898	$	41,947	$	140,635	$	112,947
	Non-GAAP operating income as a % of revenue		39.1 %		36.4 %		37.4 %		32.8 %

	Depreciation and amortization	$	6,655	$	5,990	$	19,257	$	17,577
	Capital expenditures	$	5,787	$	6,421	$	13,985	$	14,299

Unallocated Corporate Overhead		$	(42,949)	$	(45,831)	$	(131,683)	$	(140,474)
	Add back:
	Severance		36		-		36		-
	Acquisition related adjustments ⁽³⁾		2,124		5,296		9,976		23,188
	Other items ⁽⁴⁾		89		379		(661)		1,408
	Total non-GAAP adjustments to operating expense	$	2,249	$	5,675	$	9,351	$	24,596
	Unallocated corporate overhead, excluding non-GAAP adjustments	$	(40,700)	$	(40,156)	$	(122,332)	$	(115,878)

Total
	Revenue	$	743,300	$	667,951	$	2,132,943	$	1,930,088
	Operating income		132,753		92,802		303,802		242,362
	Operating income as a % of revenue		17.9 %		13.9 %		14.2 %		12.6 %
	Add back:
	Amortization related to acquisitions		28,351		24,105		90,521		65,911
	Severance		819		2,477		6,535		4,188
	Acquisition related adjustments ⁽²⁾⁽³⁾		3,507		9,882		13,899		34,123
	Site consolidation costs, impairments and other items ⁽⁴⁾		3,137		352		5,580		2,943
	Total non-GAAP adjustments to operating income	$	35,814	$	36,816	$	116,535	$	107,165
	Operating income, excluding non-GAAP adjustments	$	168,567	$	129,618	$	420,337	$	349,527
	Non-GAAP operating income as a % of revenue		22.7 %		19.4 %		19.7 %		18.1 %

	Depreciation and amortization	$	59,580	$	51,758	$	174,048	$	146,262
	Capital expenditures	$	26,185	$	35,163	$	78,706	$	76,675

(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)		This amount represents a $2.2 million charge recorded in connection with the modification of the option to purchase the remaining 8% equity interest in Vital River in the nine months ended September 28, 2019.
(3)		These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, and fair value adjustments associated with contingent consideration.
(4)		This amount relates to third-party costs, net of insurance reimbursements, associated with the remediation of the unauthorized access into the Company's information systems which was detected in March 2019.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

SCHEDULE 5
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)⁽¹⁾
(in thousands, except per share data)

	Three Months Ended						Nine Months Ended
	September 26, 2020			September 28, 2019			September 26, 2020			September 28, 2019

Net income attributable to common shareholders	$	102,909		$	72,810		$	221,113		$	171,671
Add back:
Non-GAAP adjustments to operating income (Refer to previous schedule)		35,814			36,816			116,535			107,165
Venture capital and strategic equity investment (gains) losses, net		(20,350	)		598			(32,226	)		(5,724	)
Tax effect of non-GAAP adjustments:
Non-cash tax provision (benefit) related to international financing structure ⁽²⁾		804			(20,368	)		2,990			(20,368	)
Tax effect of the remaining non-GAAP adjustments		(1,216	)		(6,073	)		(19,040	)		(18,443	)
Net income attributable to common shareholders, excluding non-GAAP adjustments	$	117,961		$	83,783		$	289,372		$	234,301

Weighted average shares outstanding - Basic		49,703			48,818			49,482			48,682
Effect of dilutive securities:
Stock options, restricted stock units and performance share units		999			897			889			945
Weighted average shares outstanding - Diluted		50,702			49,715			50,371			49,627

Earnings per share attributable to common shareholders:
Basic	$	2.07		$	1.49		$	4.47		$	3.53
Diluted	$	2.03		$	1.46		$	4.39		$	3.46

Basic, excluding non-GAAP adjustments	$	2.37		$	1.72		$	5.85		$	4.81
Diluted, excluding non-GAAP adjustments	$	2.33		$	1.69		$	5.74		$	4.72

(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)		This adjustment relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.

	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

	SCHEDULE 6
	RECONCILIATION OF GAAP REVENUE GROWTH
	TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) ⁽¹⁾


Three Months Ended September 26, 2020		Total CRL	RMS Segment	DSA Segment	MS Segment

Revenue growth, reported		11.3 %	14.6 %	9.8 %	12.9 %
Increase due to foreign exchange		(1.3)%	(1.5)%	(1.2)%	(1.4)%
Contribution from acquisitions ⁽²⁾		(2.2)%	(11.1)%	- %	- %
Non-GAAP revenue growth, organic ⁽³⁾		7.8 %	2.0 %	8.6 %	11.5 %

Nine Months Ended September 26, 2020		Total CRL	RMS Segment	DSA Segment	MS Segment

Revenue growth, reported		10.5 %	2.1 %	13.8 %	9.2 %
Decrease due to foreign exchange		- %	- %	- %	0.5 %
Contribution from acquisitions ⁽²⁾		(4.8)%	(8.2)%	(5.1)%	- %
Non-GAAP revenue growth, organic ⁽³⁾		5.7 %	(6.1)%	8.7 %	9.7 %

(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)		The contribution from acquisitions reflects only completed acquisitions.
(3)		Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign exchange.

Contacts

Investor:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com

Media:
Amy Cianciaruso
Corporate Vice President,
Public Relations
781.222.6168
amy.cianciaruso@crl.com

Document and Entity Information	Oct. 29, 2020
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 29, 2020
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-15943
Entity Tax Identification Number	06-1397316
Entity Address, Address Line One	251 Ballardvale Street
Entity Address, City or Town	Wilmington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01887
City Area Code	781
Local Phone Number	222-6000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001100682
Title of 12(b) Security	Common stock, $0.01 per share
Trading Symbol	CRL
Security Exchange Name	NYSE

Document and Entity Information

Oct. 29, 2020

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 29, 2020

Entity Registrant Name

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Entity Incorporation, State or Country Code

Entity File Number

001-15943

Entity Tax Identification Number

06-1397316

Entity Address, Address Line One

251 Ballardvale Street

Entity Address, City or Town

Wilmington

Entity Address, State or Province

Entity Address, Postal Zip Code

01887

City Area Code

781

Local Phone Number

222-6000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0001100682

Title of 12(b) Security

Common stock, $0.01 per share

Trading Symbol

CRL

Security Exchange Name

NYSE

Delaware	001-15943	06-1397316
(State or Other	(Commission File Number)	(IRS Employer
Jurisdiction of Incorporation)		Identification No.)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.01 per share		CRL		New York Stock Exchange

		CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Date: October 29, 2020	By:	/s/ Matthew L. Daniel
		Matthew L. Daniel, Corporate Senior Vice President,
		General Counsel, Corporate Secretary & Chief Compliance Officer

Exhibit No.		Description

99.1		Press release dated October 29, 2020.